Rasna Therapeutics, Inc. (RASP) financial statements (2021 and earlier)
Company profile
| Business Address |
420 LEXINGTON AVENUE NEW YORK, NY 10170 |
| State of Incorp. | NV |
| Fiscal Year End | September 30 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 12/31/2019 Q1 | 9/30/2019 Q4 | 6/30/2019 Q3 | 3/31/2019 Q2 | 12/31/2018 Q1 | 9/30/2018 Q4 | 6/30/2018 Q3 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 28 | 50 | 58 | 42 | 88 | 43 | 20 | ||
| Cash and cash equivalents | 28 | 50 | 58 | 42 | 88 | 43 | 20 | ||
| Receivables | 14 | 29 | 77 | 133 | 238 | 105 | |||
| Other undisclosed current assets | 8 | 7 | 32 | 43 | 67 | 67 | 162 | ||
| Total current assets: | 36 | 72 | 119 | 163 | 287 | 347 | 287 | ||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 2 | 2 | 2 | 3 | 4 | 5 | 7 | ||
| Intangible assets, net (including goodwill) | 4,872 | 2,959 | 4,872 | 4,872 | 4,872 | 2,959 | 4,872 | ||
| Goodwill | 2,723 | 2,723 | 2,723 | 2,723 | 2,723 | 2,723 | 2,723 | ||
| Intangible assets, net (excluding goodwill) | 2,149 | 236 | 2,149 | 2,149 | 2,149 | 236 | 2,149 | ||
| Other undisclosed noncurrent assets | 1,913 | 1,913 | 0 | ||||||
| Total noncurrent assets: | 4,874 | 4,874 | 4,875 | 4,875 | 4,877 | 4,878 | 4,879 | ||
| TOTAL ASSETS: | 4,910 | 4,946 | 4,994 | 5,038 | 5,164 | 5,225 | 5,167 | ||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 1,593 | 1,591 | 1,648 | 1,583 | 1,536 | 1,422 | 1,178 | ||
| Accounts payable | 864 | 830 | 801 | 720 | 570 | ||||
| Accrued liabilities | 727 | 753 | 735 | 702 | 608 | ||||
| Other undisclosed accounts payable and accrued liabilities | 1,593 | 1,648 | |||||||
| Debt | 331 | 258 | 245 | 235 | |||||
| Due to related parties | 556 | 550 | 550 | 550 | 550 | 550 | 550 | ||
| Other undisclosed current liabilities | 265 | 137 | 9 | ||||||
| Total current liabilities: | 2,480 | 2,405 | 2,456 | 2,378 | 2,321 | 2,109 | 1,736 | ||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 11 | ||||||||
| Deferred tax liabilities, net | ✕ | ✕ | ✕ | ✕ | 11 | ||||
| Other undisclosed noncurrent liabilities | 3 | 3 | 11 | 11 | |||||
| Total noncurrent liabilities: | 3 | 3 | 11 | 11 | 11 | ||||
| Total liabilities: | 2,483 | 2,409 | 2,466 | 2,378 | 2,331 | 2,120 | 1,736 | ||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent | 2,426 | 2,537 | 2,527 | 2,660 | 2,833 | 3,106 | 3,430 | ||
| Common stock | 69 | 69 | 69 | 69 | 69 | 69 | 69 | ||
| Additional paid in capital | 19,827 | 19,780 | 19,710 | 19,633 | 19,540 | 19,412 | 19,331 | ||
| Accumulated deficit | (17,470) | (17,312) | (17,252) | (17,042) | (16,777) | (16,375) | (15,970) | ||
| Total stockholders' equity: | 2,426 | 2,537 | 2,527 | 2,660 | 2,833 | 3,106 | 3,430 | ||
| TOTAL LIABILITIES AND EQUITY: | 4,910 | 4,946 | 4,994 | 5,038 | 5,164 | 5,225 | 5,167 | ||
Income statement (P&L) ($ in thousands)
| 12/31/2019 Q1 | 9/30/2019 Q4 | 6/30/2019 Q3 | 3/31/2019 Q2 | 12/31/2018 Q1 | 9/30/2018 Q4 | 6/30/2018 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (149) | (61) | (192) | (263) | (399) | (405) | (809) | |
| Operating loss: | (149) | (61) | (192) | (263) | (399) | (405) | (809) | |
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | (9) | (7) | (18) | (2) | (2) | 2 | 5 | |
| Interest and debt expense | (9) | (7) | (21) | |||||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | 9 | (21) | 21 | |||||
| Loss from continuing operations before equity method investments, income taxes: | (158) | (95) | (210) | (265) | (401) | (403) | (804) | |
| Other undisclosed income from continuing operations before income taxes | 28 | |||||||
| Loss from continuing operations before income taxes: | (158) | (68) | (210) | (265) | (401) | (403) | (804) | |
| Other undisclosed income (loss) from continuing operations | 8 | (2) | ||||||
| Net loss available to common stockholders, diluted: | (158) | (60) | (210) | (265) | (401) | (405) | (804) | |
Comprehensive Income ($ in thousands)
| 12/31/2019 Q1 | 9/30/2019 Q4 | 6/30/2019 Q3 | 3/31/2019 Q2 | 12/31/2018 Q1 | 9/30/2018 Q4 | 6/30/2018 Q3 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (158) | (60) | (210) | (265) | (401) | (405) | (804) | |
| Comprehensive loss, net of tax, attributable to parent: | (158) | (60) | (210) | (265) | (401) | (405) | (804) | |
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.